By contrast, the addition of pembrolizumab to eribulin did not provide any significant ORR and progression-free survival (PFS) advantage compared to eribulin alone in a randomized phase II study including 88 pretreated HR+/HER2− aBC patients (NCT03051659). The gene discussed is HR; the disease is aneurysmal bone cyst.